Bico Group Ab Class B · OMXSTO:BICO
Bico Group Ab Class B — JPM Healthcare Conference 2024
27 slides from Bico Group Ab Class B's conference presentation, Jan 10, 2024
Slide 1: JPM Healthcare Conference 2024
JPM HEALTHCARE CONFERENCE 2024 – JANUARY 10, 2024 MARIA FORSS, CEO AND PRESIDENT BICO GROUP AB
Slide 2: Disclaimer
DISCLAIMER You must read the following before continuing. The following for publication, release or distribution in the United States, the affect the extent to which a particular projection is realised. applies to this document and the information provided in this United Kingdom, Australia, Canada o
Slide 3: Vision and Mission
VISION AND MISSION We create the future of life-saving treatments by aiming to reduce the organ shortage and speed up drug development by providing accessible life science solutions that combine biology and technology.
Slide 4: Maria Forss
Maria Forss CEO and President, BICO Group AB
Slide 5: BICO in Figures
BICO in Figures Founded in 2016 65+ 950+ 14 Global Presence Employees Companies No of Markets SEK 2.2bn 32,000+ 11,000+ Net Sales Installed Publications FY 2022 Instruments
Slide 6: Powering a Healthcare Shift with Bioconvergence
Powering a Healthcare Shift with Bioconvergence Bioconvergence Software and Engineering – Technological Development Technological Development Materials Genetic Therapy Science Biotechnology – AI & Big Data Digitization of Biological Data Computing Biological Drugs Data Chemical Drugs
Slide 7: BICO Enables the Bioconvergence Journey
BICO Enables the Bioconvergence Journey CELLINK founded in 2016. Portfolio companies acquired between 2018-2022 Bioprinting Technologies Single Cell Printing Organoid/Spheroid Printing Multi-Cell Printing Tissue Printing Technologies Enabling Life Saving Treatments
Slide 8: BICO Enables the Bioconvergence Journey
BICO Enables the Bioconvergence Journey CELLINK founded in 2016. Portfolio companies acquired between 2018-2022 Complementary Technologies Bioprinting Technologies Single Cell Printing Organoid/Spheroid Printing Multi-Cell Printing Tissue Printing – Laboratory Automation – Liquid Handling – Microsco
Slide 9: Large Global TAM Provides Good Opportunities for Growth
Large Global TAM* Provides Good Opportunities for Growth Estimated to USD ~121bn, Growing at ~12% CAGR CAGR (2023-28) 213 +12% 190 +15% Bioprinting 170 TAM: USD 19bn 152 136 +10% Bioautomation 121 TAM*: USD 33bn +12% Biosciences TAM*: USD 85bn 2023 2024 2025 2026 2027 2028 Current Global TAM* (USDbn
Slide 10: Key Trends in BICO's Markets
Key Trends in BICO’s Markets – Increased focus on – Growing demand – Growing adoption of personalized and for integrated and in-vitro testing instead regenerative medicine automated workflows of animal testing* in laboratories – Increasing adoption of – Prevailing genetic bioprinting in the – Higher
Slide 11: Tissue Engineering is Unlocking a New Frontier in Healthcare
1. Tissue Engineering is Unlocking a New Frontier in Healthcare
Slide 12: BICO Has a Unique Position in the Bioprinting Landscape
BICO Has a Unique Position in the Bioprinting Landscape Installed Base Competitor A Competitor B Competitor C Competitor D Competitor E Competitor F Competitor G Complexity of Printed Tissue Cornea Organ Tissue
Slide 13: Bioprinting Patient-Specific Tumor Models for Individualized Drug Testing
BICO Customer Case - Tissue Engineering: Carcinotech Bioprinting Patient-Specific Tumor Models for Individualized Drug Testing
Slide 14: The Challenge
The Challenge • The complex nature of cancer means that there are still only limited pathways for treatment • Personalized medicine is a promising avenue • Requires patient specific level of research
Slide 15: The Solution
The Solution Mix cells into Bioprint Culture into Drug CELLINK tumor patient efficacy LAMININK models specific testing bioink models
Slide 16: The Impact
The Impact Enabling the Driving forward development of a personalized physiologically approach in cancer relevant models treatment Decreasing the Reducing the use of animals time to find for preclinical optimal testing candidates for treatment therapies
Slide 17: Automation Positively Transforms Businesses and the Lives of People
2. Automation Positively Transforms Businesses and the Lives of People
Slide 18: The Global Challenge
The Global Challenge Long and costly clinical stages combined with low success rate comprise a global challenge for the drug development industry Drug Pre-Clinical Clinical Regulatory Discovery Trials Trials Approval 4-5 years 1 year 4-7 years 1-2 years 12+ years References: Phrma.org, Tufts center
Slide 19: The Global Challenge
The Global Challenge Long and costly clinical stages combined with low success rate comprise a global challenge for the drug development industry Drug Pre-Clinical Clinical Regulatory Discovery Trials Trials Approval 4-5 years 1 year 4-7 years 1-2 years 12+ years References: Phrma.org, Tufts center
Slide 20: Improving Care for Chronic Diseases through Laboratory Automation
Improving Care for Chronic Diseases through Therapeutic Development that Depends on Laboratory Automation BICO Customer Case – Lab Automation: AstraZeneca Improving Care for Chronic Diseases through Therapeutic Development that Depends on Laboratory Automation
Slide 21: The Challenge
The Challenge Biopharmaceutical Robotics and automated Each discrete scale-down manufacturing processes scale-down models are model is currently run are highly complex and frequently used in the on islands of automation, require regulatory lab to develop these requiring manual approval to safely pro
Slide 22: The Solution
The Solution Cell culture GBG-driven Samples purified GBG-driven Analytics manufacturing automation to enable automation measure process conditions retrieves samples measurement of retrieves and product tested across for purification quality attributes samples quality attributes numerous bioreactors
Slide 23: The Impact
The Impact Reduce downstream Increase existing Maximize productivity process and assay equipment capacity of development scientists development by up to develop and labs by a minimum to 75% biopharmaceutical of 200% manufacturing processes by 400%
Slide 24: BICO Leads the Way in Solving the Challenges in Drug Development
BICO Leads the Way in Solving the Challenges in Drug Development with Speed, Accuracy, and Efficiency Speed • Reducing the time to find optimal candidates for treatment therapies Accuracy • Driving forward a personalized approach in treatment • Enabling the development of physiologically relevant mo
Slide 25: BICO Technologies Enabling Life Saving Treatments
BICO Technologies Enabling Life Saving Treatments – End to end delivery competence – Leading in innovation – unique position in the bioprinting landscape – BICO’s core markets exhibits double-digit growth – Portfolio and offering – relevant both today and tomorrow – Highly competent team – inhouse R
Slide 26: deen etic
deen etic « REVOLUTION: oe
Slide 27: Slide 27